

Hepatoprotective Activity of Quercetin against Acrylonitrile-Induced Hepatotoxicity in Rats

Osama M. Abo-Salem¹, Mohamed F. Abd-Ellah¹, and Mabrouk M. Ghonaim²

¹Department of Pharmacology & Toxicology, Faculty of Pharmacy, Al-Azhar University, Nasr City, Cairo, Egypt

²Department of Microbiology and Immunology, Faculty of Medicine, Menoufiya University, Shebin El-Kom, Egypt

Received 18 April 2011; revised 8 June 2011; accepted 24 June 2011

ABSTRACT: Acrylonitrile is a potent hepatotoxic, mutagen, and carcinogen. A role for free radical-mediated lipid peroxidation in the toxicity of acrylonitrile has been suggested. The present study was designed to assess the hepatoprotective effect of quercetin against acrylonitrile-induced hepatotoxicity in rats. Liver damage was induced by oral administration of acrylonitrile (50 mg/kg/day/5 weeks). Acrylonitrile produced a significant elevation of malondialdehyde (138.9%) with a marked decrease in reduced glutathione (72.4%), and enzymatic antioxidants; superoxide dismutase (81%), and glutathione peroxidase (53.2%) in the liver. Serum aspartate aminotransferase, alanine aminotransferases, direct bilirubin, and total bilirubin showed a significant increase in acrylonitrile alone treated rats (115.5%, 110.8%, 1006.8%, and 1000.8%, respectively). Pretreatment with quercetin (70 mg/kg/day/6 weeks) and its coadministration with acrylonitrile prevented acrylonitrile-induced alterations in hepatic lipid peroxides and enzymatic antioxidants as well as serum aminotransferases and bilirubin. Histopathological findings supported the biochemical results. We suggest that quercetin possess hepatoprotective effect against acrylonitrile-induced hepatotoxicity through its antioxidant activity. © 2011 Wiley Periodicals, Inc. *J Biochem Mol Toxicol* 25:386–392, 2011; View this article online at wileyonlinelibrary.com. DOI 10.1002/jbt.20406

KEYWORDS: Hepatoprotective; Rats; Acrylonitrile; Quercetin; Flavonoids

INTRODUCTION

Acrylonitrile (ACN) is widely used in the production of many industrial products such as synthetic fibers, nitrile rubbers, resins, plastics, and pesticide fumigants for grains. It is also used as an intermediate in the synthesis of antioxidants, surface coatings, adhesives, and dyes [1]. In clinical practice, ACN is used in the synthesis of high permeable dialysis tubings [2], and artificial membranes to encapsulate Langerhan's islet implants [3]. Moreover, ACN has been found in water, occupational environments, food, and cigarette smoke [3].

ACN is metabolized through different metabolic pathways: (a) enzymatic (glutathione-S-transferase "GST") [4] and nonenzymatic conjugation with reduced glutathione (GSH) and protein sulfhydryl groups (the major route) [5] and (b) oxidation by the cytochrome P-450 to yield 2-cyanoethylene oxide and cyanide (CN) (the critical step in ACN toxicity) [6].

Chronic exposure of rats to ACN has been reported to produce a dose-related increase in glial cell tumors (astrocytomas) [7]. Moreover, previous studies have shown that ACN exposure was associated with induction of oxidative stress (OS) and reduction in tissue content of cysteine [8], lysine, methionine, and GSH as well as disturbance of pyruvate metabolism [9]. Furthermore, increased lipid peroxidation, oxidative damage (OD) of DNA, and deficiency of antioxidant protection in rat brain were reported following ACN chronic exposure [10]. Acute ACN toxicity in rats included tissue damage of important organs (brain, liver, lung, and kidney) [11], gastric and duodenal ulceration [5], and adrenocorticolysis [11].

Flavonoids are characterized by many pharmacodynamic actions as hypolipidemic, cardiotoxic, hypotensive, antiarrhythmic, spasmolytic, sedative, diuretic, hypothermic, and antibacterial effects [12]. Quercetin, a flavonoid antioxidant, is one of the flavonols that are commonly found in vegetables [13].

Correspondence to: Osama M. Abo-Salem; e-mail: oabosalem@yahoo.com

Present address of Osama M. Abo-Salem and Mabrouk M. Ghonaim: Department of Medical Laboratories, College of Applied Medical Sciences, Taif University, Saudi Arabia.

© 2011 Wiley Periodicals, Inc.

Previous studies showed that quercetin protected the liver and lung against toxicity induced by ammonium fluoride [14] and beta-cell damage induced by streptozotocin in rat pancreas [15]. The liver is the main site of oxidative and detoxifying processes. In many diseases, elevated biomarkers of OS were detected in the liver at early stages [16].

This study was performed to investigate a potential protective effect of quercetin treatment on liver OS in ACN-induced hepatic toxicity in rats.

MATERIALS AND METHODS

Chemicals

All chemicals and kits were purchased from Sigma-Aldrich Company (St. Louis, MO) and Biodiagnostics Company (Cairo, Egypt).

Animals

Adult male albino rats (130–150 g) of Wistar strain were used and purchased from the National Institute of Cancer, Cairo, Egypt. They were housed in clean cages, fed with commercial rat chow and water ad libitum under standard laboratory conditions. All animal experiments were conducted according to the regulations of the Committee on Bioethics for Animal Experiments of Al-Azhar University.

Experimental Design

Fifty rats were used and divided into five groups ($n = 10$ in each group).

- Group I: served as a control group (*control*) and received distilled water, p.o., daily for 6 weeks.
- Group II: served as vehicle treated group (*vehicle*) and received ethanol in water (1:9), p.o., daily for 6 weeks.
- Group III: Quercetin alone treated group (*Q*) and received daily quercetin for 6 weeks in a dose of 70 mg/kg bwt, p.o., dissolved in the vehicle [13,17].
- Group IV: served as ACN alone treated group (*ACN*) and received an aqueous solution of ACN (50 mg/kg bwt, p.o., half of the LD50), once daily for 5 weeks [18].
- Group V: served as quercetin + ACN treated group (*Q + ACN*) and received quercetin (70 mg/kg bwt) 1 week before starting ACN treatment as well as concomitantly with ACN (50 mg/kg bwt) once daily for

5 weeks. Animals were treated with ACN at 2 h after quercetin administration.

The dose of quercetin that was previously reported to induce maximal beneficial effects in different liver diseases was used [13]. All treatments were given in a volume of 10 mL/kg bwt.

Assessment of Serum and Hepatic Biochemical Markers

After 24 h of the last dose, the animals were sacrificed under ether anesthesia and blood was collected. The blood sample of each animal was collected separately by carotid artery into sterilized dry centrifuge tubes and allowed to coagulate for 30 min. Serum was separated by centrifugation at 3000 rpm for 15 min. Serum levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT), and bilirubin were estimated using an autoanalyzer [19,20].

The livers were removed immediately, washed with ice-cold saline, and a 10% homogenate was prepared in phosphate buffered saline (pH 7.0). The homogenate was centrifuged at 3000 rpm for 15 min at 4°C, and the supernatant was used for estimation of reduced GSH [21], malondialdehyde (MDA) [22], superoxide dismutase (SOD) [23], glutathione peroxidase (GSHpx) [24], and protein [25]. Livers of two rats were preserved in 10% formaldehyde solution for the histological study.

Histopathological Examination

Liver sections were cut at 5- μ m thickness, using a rotary microtome and stained with haematoxylin and eosin [26]. Sections were examined and photographed under a light microscope.

Statistical Analysis

The results were expressed as mean \pm SEM and statistically analyzed using one-way analysis of variance (ANOVA) followed by Student–Tukey–Kramer test. P values ≤ 0.05 were considered significant. The percentage of change was calculated as follows: (treated – control)/(control) $\times 100$.

RESULTS

Liver Function Tests

The effects of quercetin on ACN-induced liver damage in rats with reference to biochemical changes

TABLE 1. Effect of Acrylonitrile and/or Quercetin on Serum Levels of Aminotransferases and Bilirubin

Treatment	Studied Liver Function Tests			
	AST (IU/L)	ALT (IU/L)	Total Bilirubin (mg/dL)	Direct Bilirubin (mg/dL)
Control	42.63 ± 2.49	58.38 ± 4.77	0.117 ± 0.006	0.029 ± 0.003
Vehicle	41.50 ± 3.26	63.25 ± 6.22	0.112 ± 0.008	0.030 ± 0.002
Q	45.13 ± 3.67	63.88 ± 4.86	0.111 ± 0.008	0.034 ± 0.003
ACN	91.88 ± 4.20 ^{a,b,c}	123.1 ± 5.54 ^{a,b,c}	1.288 ± 0.084 ^{a,b,c}	0.321 ± 0.023 ^{a,b,c}
ACN + Q	52.50 ± 4.28 ^d	63.13 ± 4.98 ^d	0.140 ± 0.005 ^d	0.038 ± 0.002 ^d

Data are expressed as mean ± SEM of eight rats for each group.

Q: quercetin; ACN: acrylonitrile.

^aSignificantly different from control group.

^bSignificantly different from vehicle treated group.

^cSignificantly different from rats treated with Q alone.

^dSignificantly different from group treated with ACN alone using one-way ANOVA with Tukey–Kramer test at $P \leq 0.05$.

in serum are presented in Table 1. At the end of the 5 weeks treatment, ACN alone treated animals showed a significant increase in the serum levels of AST (115.5%), ALT (110.9%), direct bilirubin (1006.8%), and total bilirubin (1000.8%) as compared to the control group. On the other hand, treatment of rats with quercetin (1 week before and concomitantly with ACN) prevented the ACN-induced increase in serum AST, ALT, and bilirubin as compared to the ACN alone treated group.

Lipid Peroxides and Antioxidant Levels in the Liver

The hepatic MDA content was significantly increased by 138.9% in ACN-treated rats. On the other hand, there was a marked reduction in the hepatic content of GSH, SOD, and GSHpx amounting to 72.4%, 81%, and 53.2%, respectively, in ACN alone treated animals. Pretreatment with quercetin and itscoadministration with ACN ameliorated the alter-

tations in the hepatic MDA, GSH, SOD, and GSHpx (Table 2).

Histopathological Findings

Figure 1 shows that there were significant changes in microscopic photographs of the liver in ACN alone treated animals as compared to the normal control group. Normal cellular architecture with distinct hepatic cells, sinusoidal spaces, and a central vein were observed in the normal control, vehicle, and quercetin alone treated groups (Figures 1A, 1B, and 1C). On the other hand, the ACN alone treated group exhibited histopathological changes, such as portal inflammation and tissue disorganization. The hepatocytes adjoining the portal tract show ballooning degeneration and droplet fatty change with infiltrating lymphocytes (Figure 1D). Pretreatment of rats with quercetin prevented the histopathological changes associated with hepatic toxicity induced by ACN. However, mild inflammatory cell infiltration, and fatty change are still observed (Figure 1E).

TABLE 2. Effect of Acrylonitrile and/or Quercetin on Liver Content of Oxidant and Antioxidant Parameters

Treatment	Studied Hepatic Tissue Parameters			
	GSH ($\mu\text{g/g}$ tissue)	MDA (nmol/mg protein)	GSHpx (nmol/mg protein/min)	SOD (U/mg protein)
Control	16.54 ± 0.53	3.24 ± 0.10	1208.0 ± 68.19	13.95 ± 1.05
Vehicle	15.53 ± 0.69	3.33 ± 0.27	1205.0 ± 77.93	13.95 ± 1.18
Q	15.20 ± 0.86	3.57 ± 0.22	1231.7 ± 95.67	14.98 ± 0.73
ACN	4.57 ± 0.27 ^{a,b,c}	7.74 ± 0.39 ^{a,b,c}	565.3 ± 44.10 ^{a,b,c}	2.58 ± 0.17 ^{a,b,c}
ACN + Q	14.00 ± 1.25 ^d	3.97 ± 0.34 ^d	1239.2 ± 61.45 ^d	16.53 ± 1.10 ^d

Data are expressed as mean ± SEM of eight rats for each group.

Q: quercetin; ACN: acrylonitrile.

^aSignificantly different from control group.

^bSignificantly different from vehicle treated group.

^cSignificantly different from rats treated with Q alone.

^dSignificantly different from group treated with ACN alone using one-way ANOVA with Tukey–Kramer test at $P \leq 0.05$.




FIGURE 1. Histopathological changes of rat liver treated with ACN and/or quercetin (H&E stain; $\times 300$). (A): Normal rat liver, (B): vehicle, (C): quercetin alone, (D): positive control (ACN), (E): quercetin + ACN. Sections (A), (B), and (C) show a normal structure of the hepatic cells. Section (D) shows hepatocyte degeneration, large droplet fatty change and infiltrating lymphocytes. Treatment of rats with quercetin + ACN shows that mild inflammatory cell infiltration and fatty change are still observed (section (E)).



DISCUSSION

Several studies have indicated the role of OS in ACN toxicity [27,28]. The major pathway of ACN elimination is its conjugation with GSH to form mercapturic acid through GST and production of CN via cytochrome P450 [4].

The present study showed a decrease in both enzymatic (SOD and GSHpx) and nonenzymatic (GSH) antioxidants as well as an increased level of lipid per-

oxidation (represented by MDA) in the ACN alone treated rats. Similar findings were reported by Mahalakshmi et al. [28]. GSHpx is responsible for the removal of ROS, such as peroxides. ACN may diminish the activities of GSHpx enzyme by inhibition of enzyme synthesis or inactivation by conjugation [28,29]. Free radical scavengers such as GSH, vitamin E, silymarin, hesperidine, taurine, and quercetin exist in their interconvertible forms and participate in the detoxification of reactive oxygen species (ROS) [18,28]. By depleting

GSH, ACN may decrease the antioxidant levels in cells leading to an overall increase in intracellular ROS and OD. CN has been shown to induce OS in mice brain by inhibiting mitochondrial respiratory chain, catalase, and GSHpx [30]. GSH participates in enzymatic reduction of membrane hydroperoxy-phospholipids and prevents the formation of secondary alkoxyl radicals when peroxides are homolyzed [31].



where PH is phospholipids, La is fatty acid, Se is selenium, Gpx is glutathione peroxidase, GSSG is oxidized glutathione [32].

Binding of ACN to GSH results in induction of OS and impaired regeneration of other antioxidants [33]. Studies with ^{14}C ACN have shown that ACN covalently binds with sulfhydryl groups of protein [34], macromolecules, and nucleic acids [1]. This explains the reduction in the GSH content in cells and increases their susceptibility to OD.

Our results indicated that quercetin treatment significantly decreased ACN-induced lipid peroxidation, accompanied by the increased hepatic GSH content and enhanced activities of SOD and GSHpx. Quercetin attenuates lipid peroxidation either by scavenging and inactivating H_2O_2 and hydroxyl radicals or by binding with copper and iron [13,35–37]. Quercetin may also terminate lipid peroxidation by inducing enzymatic and nonenzymatic antioxidants. Our results are consistent with those of Wadsworth and Koop, [38] who demonstrated that quercetin improved hepatic levels of GSH, MDA, SOD, and GSHpx in diabetic rats, possibly by preventing cytotoxic effects of nitric oxide (NO) and ROS.

The present study revealed that ACN (50 mg/kg) produced significant elevations in ALT, AST, and bilirubin. These parameters have been reported to be sensitive indicators of liver injury [27]. Increased levels of aminotransferases showed that the integrity of hepatocytes was abnormal in ACN alone treated rats, resulting in the release of these enzymes into the systemic circulation [39]. Administration of quercetin prevented ACN-induced elevations of AST (50.9%), ALT (48.1%), and total (91.4%) and direct bilirubin (89.4%) as compared to ACN alone treated group. Kebieche et al. [40] reported that quercetin ameliorated the altered enzyme levels and protected rat liver against chemicals- or drugs-induced hepatotoxicity. Quercetin may inhibit lipid peroxidation by blocking

xanthine oxidase, binding with iron and/or copper [41], scavenging hydroxyl, peroxy, and superoxide radicals [42], increasing vitamin C absorption [43], and inducing nitric oxide synthase inhibitor (decreasing NO and peronitrate generation) [44]. Histopathological investigations demonstrated that ACN-induced various degenerative changes in the hepatocytes, which confirmed the biochemical data. Treatment with quercetin obviously mitigated the histopathological changes induced by ACN.

CONCLUSION

ACN-induced hepatic damage might be related to OS. Treatment with quercetin decreased the ACN-induced elevation in biochemical parameters and was effective in structural improvement of liver. Our results suggest that quercetin may have a potential therapeutic effect against ACN-induced liver injury.

ACKNOWLEDGMENTS

The authors express their deepest gratitude to Dr. Hala F. Abd-Ellah, Zoology Department of Girls, College of Arts, Science and Education, Ain Shams University, Cairo, Egypt, for her kind help in performing histopathological examination.

REFERENCES

1. Pilon D, Roberts AE, Rickert AE, Rickert DC. Effect of GSH depletion on the uptake of acrylonitrile vapours and on its irreversible association with tissue macromolecules. *Toxicol Appl Pharmacol* 1988;95:265–278.
2. Ward RA, Schaefer RM, Falkenhagen D, Joshua MS, Heidland A, Klinkmann H, Gurland HJ. Biocompatibility of a new high-permeability modified cellulose membrane for haemodialysis. *Nephrol Dialysis Transplant* 1993;8(1):47–53.
3. Kessler L, Pinget M, Aprahamian M, Dejardin P, Damage C. In vitro and in vivo studies of the properties of an artificial membrane for pancreatic islet encapsulation. *Horm Metab Res* 1991;23:312–317.
4. Fennell TR, Kedderis GL, Sumner SC. Urinary metabolites of (1,2,3- ^{13}C) acrylonitrile in rats and mice detected by ^{13}C nuclear magnetic resonance spectroscopy. *Chem Res Toxicol* 1991;4:678–687.
5. Szabo S, Bailey KA, Boor PJ, Jaeger RJ. Acrylonitrile and tissue glutathione: differential effect of acute and chronic interactions. *Biochem Biophys Res Commun* 1977;79:32–37.
6. Guengerich FP, Geiger LE, Hogg LL, Wright PL. In vitro metabolism of acrylonitrile to 2-cyanoethylene oxide, reaction with glutathione and irreversible binding to proteins and nucleic acids. *Cancer Res* 1981;41:4925–4933.

7. Bigner DD, Bigner SH, Burger JD, Shelburne TJD, Friedman HS. Primary brain tumors in Fisher 344 rats chronically exposed to acrylonitrile in their drinking water. *Food Chem Toxicol* 1986;24:129–137.
8. Campian EC, Benz FW. The acute lethality of acrylonitrile is not due to metabolic arrest. *Toxicology* 2008;253(1–3):104–109.
9. Ahmed AE, Hussein GT. Acrylonitrile. In: Snyder R., Buchler DR, Reed DJ, editors. *Toxicity and metabolism of industrial solvents: Nitrogen and phosphorous solvents*, 2nd edition. Amsterdam, The Netherlands: Elsevier Science Publishers BV; 1990. Vol 2, pp 306–323.
10. Kamendulis LM, Jiang J, Xu Y, Klaunig JE. Induction of oxidative stress and oxidative damage in rat glial cells by acrylonitrile (ACN). *Carcinogenesis* 1999;20:1555–1560.
11. Farooqui MYH, Ahmed AE. In vivo interactions of acrylonitrile with macromolecules in rats. *Chem Biol Interact* 1983;47:363–371.
12. Formica JV, Regelson W. Review of the biology of quercetin and related bioflavonoids. *Food Chem Toxicol* 1995;33:1061–1080.
13. Peres W, Tun MJ, Mato S, Collado PS, Marroni N, Iez-Gallego J. Hepatoprotective effects of the flavonoid quercetin in rats with biliary obstruction. *J Hepatol* 2000;33:742–750.
14. Humiczewska M, Hermach U, Put A. The effect of the pollen extracts quercetin and cernitin on the liver, lungs, and stomach of rats intoxicated with ammonium fluoride. *Folia Biol (Krakow)* 1994;42(3–4):157–166.
15. Coskun O, Kanter M, Korkmaz A, Oter S. Quercetin, a flavonoid antioxidant, prevents and protects streptozotocin-induced oxidative stress and beta-cell damage in rat pancreas. *Pharmacol Res* 2005;51(2):117–123.
16. Stadler K, Jenei V, Bolcschazy G, Somogyi A, Jakus J. Increased nitric oxide levels as an early sign of premature aging in diabetes. *Free Radical Biol Med* 2003;35:1240–1251.
17. Lopez-Reyes AG, Arroyo-Curras M, Cano BG, Lara-Diaz V, Guajardo-Salinas GE, Islas JF, Morales-Oyarvide V, Morales-Garza LA, Galvez-Gastelum FJ, Grijalva G, Moreno-Cuevas JA. Black bean extract ameliorates liver fibrosis in rats with CCl₄-induced injury. *Ann Hepatol* 2008;7(2):130–135.
18. El-Sayed MEI-S, Abo-Salem OM, Abd-Ellah MF, Abd-Alla GM. Hesperidin, an antioxidant flavonoid, prevents acrylonitrile-induced oxidative stress in rat brain. *J Biochem Mol Toxicol* 2008;22:268–273.
19. Henry RJ, Cannon DC, Winkelman JW. *Clinical chemistry principles and techniques*. New York: Harper and Row; 1974. 822–844 pp.
20. Gambino SR. *Standard methods of clinical chemistry*. New York: Academic Press; 1965. 55–77 pp.
21. Durairaj AK, Vaiyapuri TS, Mazumder UK, Gupta M. Hepatoprotective and inhibition of oxidative stress in liver tissue of *Oxystelma esculentum* on paracetamol induced hepatic damage in rats. *Pharmacologyonline* 2007;3:52–72.
22. Uchiyama M, Mihara M. Determination of malonyl-dialdehyde precursor in tissues by thiobarbituric acid test. *Anal Biochem* 1978;86:271–278.
23. Marklund SL. Superoxide dismutase isoenzymes in tissues and plasma from New Zealand Black mice. *Mutat Res* 1985;148:129–134.
24. Paglia D, Valentine W. Studies on the quantitative and qualitative characterization of erythrocytes glutathione peroxidase. *J Lab Clin Med* 1976;70:158–169.
25. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the folin phenol reagent. *J Biol Chem* 1951;193:265–275.
26. Luna LG. In: *Manual of histology, staining methods of Armed Forces Institute of Pathology*, 3rd edition. New York: McGraw-Hill; 1968. pp 325–333.
27. Recnago RO. Carbontetrachloride hepatotoxicity status quo and future prospects. *Trends Pharmacol Sci* 1983;4:129–130.
28. Mahalakshmi K, Pushpakiran G, Anuradha CV. Taurine prevents acrylonitrile induced oxidative stress in rat brain. *Pol J Pharmacol* 2003;55:1037–1043.
29. Nerland DE, Cai J, Pierce WM, Benz FW. Covalent binding of acrylonitrile to specific rat liver glutathione-S-transferase in vivo. *Chem Res Toxicol* 2001;14(7):799–806.
30. Kanthasamy AG, Ardelt B, Malave A, Mills EM, Powley TL, Borowitz JL, Isom GE. Reactive oxygen species generated by cyanide mediate toxicity in rat pheochromocytoma cells. *Toxicol Lett* 1997;93(1):47–54.
31. Sen CK, Hanninen O. Physiological antioxidants. In: Sen CK, Packer L, Hanninen O, editors. *Exercise and oxygen toxicity*. Amsterdam, The Netherlands: Elsevier Science; 1994. pp 89–126.
32. Bao Y, Williamson G. Metabolism of hydroperoxyphospholipids in human hepatoma HepG2 cells. *J Lipid Res* 1996;37:2351–2360.
33. Esmat A, El-Demerdash E, El-Mesallamy H, Abdel-Naim AB. Toxicity and oxidative stress of acrylonitrile in rat primary glial cells: preventive effects of *N*-acetylcysteine. *Toxicol Lett* 1990;171(3):111–118.
34. Ahmed AE, Farooqui MY, Upreti RK, El-Shabrawy O. Distribution and covalent interactions of [¹⁻¹⁴C] acrylonitrile in the rat. *Toxicology* 1982;23:159–175.
35. Da Silva EJ, Diskala MK, Yamamoto N, Moon JH, Tero J. Quercetin metabolites inhibit copper ion induced lipid peroxidation in rat plasma. *FEBS Lett* 1998;430:405–409.
36. Erden M, Kahraman A. The protective effect of flavonol quercetin against ultraviolet A induced oxidative stress in rats. *Toxicology* 2000;154:21–29.
37. Sanders RA, Rauscher FM, Watkins JB. Effects of quercetin on antioxidant defense in streptozotocin-induced diabetic rats. *J Biochem Mol Toxicol* 2001;15:143–149.
38. Wadsworth TL, Koop DR. Effects of *Ginkgo biloba* extract (Egb 761) and quercetin on lipopolysaccharide-induced release of nitric oxide. *Chem Biol Interact* 2001;137:43–58.
39. Zimmerman HJ, Seeff LB. *Enzymes in hepatic disease. Diagnostic enzymology*. Philadelphia, PA: Lea and Febiger; 1970. pp 1–23.
40. Kebieche M, Lakroun Z, Lahouel M, Bouayed J, Meraihi Z, Soulimani R. Evaluation of epirubicin-induced acute oxidative stress toxicity in rat liver cells and mitochondria, and the prevention of toxicity through quercetin administration. *Exp Toxicol Pathol* 2008;25:345–355.

41. Cheng LE, Breen K. On the ability of four flavonoids, baicilin, luteolin, naringenin and quercetin to suppress the fenton reaction of the iron-ATP complex. *Biometals* 2000;13:77–83.
42. De Whalley CY, Rankin JF, Rankin SM. Flavonoids inhibit the oxidative modification of low density lipoproteins. *Biochem Pharmacol* 1990;39:1743–1749.
43. Vinson JA, Bose P. Comparative bioavailability to humans of ascorbic acid alone or in a citrus extract. *Am J Clin Nutr* 1998;48:601–604.
44. Autore G, Rastrelli L, Lauro MR, Marzocco S, Sorrentino R, Sorrentino U. Inhibition of nitric oxide synthase expression by methanolic extract of *Crescentia alata* and its derived flavonols. *Life Sci* 2001;70:523–534.